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Combined statin therapyBackground: The Coronary Drug Project demonstrated a signiﬁcant decrease in non-fatal myocardial infarction,
and total mortality using immediate release niacin (IRN). However, AIM-HIGH and HPS-2-THRIVE showed no
additional beneﬁt from adding niacin to statin therapy.
Objective
To evaluate the efﬁcacy and tolerability of IRN on low-density-lipoprotein-cholesterol (LDL-C), high-density-
lipoprotein-cholesterol (HDL-C), triglycerides, and lipoprotein (a) (Lpa) at stratiﬁed lipid levels in a monothera-
py IRN group (MTG) and a combined therapy group (CTG) statin + IRN.
Methods:We retrospectively studied 185 patients who were prescribed IRN for elevated LDL-C, triglycerides,
lipoprotein a (Lpa), or low HDL-C. All patients used the same IRN products.
Results: 157 patients had complete records. (MTG = 74 patients, CTG = 83 patients with 68 combined with
statins). Mean IRN dose = 2474 mg. Mean duration = 3.05 years.
If initial LDL-C was b130, LDL-C did not decrease signiﬁcantly with IRN. If initial LDL-C N=130, LDL-C decreased
35% inMTGvs. 32% decrease in CTG. If initial HDL-C b 40, therewas a 40% increase inMTGvs. 61% increase in CTG.
If initial triglycerides N 150, there was a 48% decrease in MTG vs. 54% decrease in CTG. Lpa decreased 49% for all
patients with initially elevated Lpa. Data except for LDL-C b 130 were signiﬁcant (p b .001).
Conclusion: Lowering LDL-C is the corner stone for decreasing cardiovascular events. IRN reduces LDL-C
signiﬁcantly when initial LDL-C N 130, but not signiﬁcantly when LDL-C b 130. Patients in AIM-HIGH and
HPS-2-THIRVE received statin therapy causing very low initial LDL-C. Our results may explain why adding niacin
to statin therapy failed in AIM-HIGH and HPS-2-THRIVE since niacin did not further lower LDL-C.
© 2015 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The ﬁrst report regarding decreasing total serum cholesterol with
immediate release niacin (IRN) was published in 1955 [1]. This initial
report was followed by a number of studies demonstrating similar ﬁnd-
ings [2–5], but most of these studies regarded reduction of total serum
cholesterol and triglycerides since high density lipoprotein-cholesterol
(HDL-C) was not frequently analyzed at that time and low density
lipoprotein-cholesterol (LDL-C) was not measured or calculated. The
seminal study regarding niacin was the Coronary Drug Project begunaspartate transaminase; CTG,
in cholesterol; IRN, immediate
rol; Lpa, lipoprotein (a); MTG,
rm Training: Students in Health
npaid consultant for Biosound
n, AZ 85750, United States.
and Ltd. This is an open access articlein 1966 [6] and concluded in 1974. This double blind, randomized,
placebo-controlled,male only, secondary prevention studydemonstrated
the efﬁcacy of niacin for decreasing deﬁnite nonfatal recurrentmyocardi-
al infarction but failed to demonstrate a signiﬁcant decrease in total mor-
tality and cause speciﬁc mortality. However, a follow-up study with
nearly complete ascertainment of the original niacin and placebo groups
at 15 years demonstrated a signiﬁcant 11% decrease in mortality for the
niacin group compared to placebo group even though the niacin group
was no longer treated after conclusion of the original study [7].
Niacin has been demonstrated over the course of other studies to in-
crease HDL-C, and decrease LDL-C, LDL particles, apoprotein B, triglycer-
ides, and lipoprotein (a) [8,9]. Epidemiologic studies suggest that these
changes in lipids would be beneﬁcial [10]. In this regard, studies more
recent than the Coronary Drug Project using longer acting niacins
have demonstrated positive results in clinical trials for reductions in
plaque and cardiovascular events [11,12]. Despite these salutary results,
niacin has not been widely used because of side effects, which include
cutaneous issues such as ﬂushing, itching, and occasional rash. Other
reported side effects include increasing fasting glucose [2], uric acid
[3], increased atrial ﬁbrillation, and gastrointestinal effects such as
abdominal pain, diarrhea, and decreased appetite [6]. These side effectsunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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more slowly released to reduce the side effects, particularly ﬂushing.
Many of these products are nonprescription preparations sold as food
additives. Approximately a decade ago an extended release form
became a prescription medication that has gained favor with many
physicians because of its once daily dosage and presumed decrease in
ﬂushing [13]. Further, studies using longer acting niacins with or
without a statin have demonstrated positive results in clinical trials
[11,12]. The IRN form is currently seldom used today. The extended
release prescription product in conjunction with intensive statin and
other therapy was recently used in a clinical trial, AIM-HIGH [9],
which failed to demonstrate that adding this niacin preparation provid-
ed an additional beneﬁt beyond that of statins combined with other
lipid treatments. Further, the HPS-2-THRIVE [14] study demonstrated
a higher incidence of adverse drug reactions in the simvastatin-
extended release niacin–laropiprant (with or without ezetimibe)
group than in the control statin arm without signiﬁcant additional
reduction in cardiovascular events. Thus, results for use of longer acting
niacin forms have given inconsistent results. The major purpose of
adding niacin in most studies has been to increase HDL-C and niacin
products have been used in conjunction with statins and ezetimibe to
lower LDL-C. Whether raising HDL-C pharmacologically is useful
remains an unresolved issue [15], but lowering LDL-C has been demon-
strated in many studies to reduce cardiovascular events [16,17]. Niacin
also reduces LDL-C and the immediate release form may reduce LDL-C
more that the extended release form.
Immediate release niacin is very inexpensive compared to a pre-
scription extended release form and the immediate release form has
been used in our lipid clinic for many years. The purpose of the current
study was 1) to determine at what lipid levels IRN causes the greatest
changes in LDL-C, HDL-C, lipoprotein a, and triglycerides 2) to deter-
mine the side effects of a more modern immediate release preparation
than that used in the Coronary Drug Project and 3) and to evaluate
the lipid results of immediate release niacin as monotherapy and as an
addition to prior statin therapy.
2. Methods
This was a retrospective study of all patients recommended to take
immediate release niacin (IRN) in a lipid clinic between 1980 and
2013. Study datawere retrieved frompaper charts or electronic records.
The study was approved by the Institutional Review Boards of the Uni-
versity of Arizona and informed consentwas deemed unnecessary since
data were kept in an anonymous manner.
2.1. Patients
Treatment with IRN was recommended for patients N18 years. Pa-
tients were prescribed niacin due to several common etiologies: statin
and other LDL-C lowering medication intolerance with elevated LDL-C,
considerably elevated triglyceride, very low HDL, elevated Lpa, and as
an adjunct for those with familial hyperlipidemia whose LDL-C
remained substantially elevated after statin therapy.
2.2. Niacin protocol
All patients used the same preparations of immediate release niacin
(Rugby Pharmaceutical Company 100 mg with the product # 0536–
4076-01-2 and 500 mg with the product numbers of 0-0536-4078-10-
8). All patients were started on the same niacin protocol with the initial
dose of 50 mg taken following meals 3 times per day. The dose was
doubled every 2 weeks. Chewable 81 mg aspirin was used on alternate
weeks or as necessary to prevent ﬂushing. To stop a severe ﬂush
patients were instructed to chew three 81 mg aspirins and drink a
large glass of water. Aspirin was discontinued as soon as patients no
longer experiencedﬂushing. Themaximal daily dose of IRNwas decidedby correction of the lipid abnormality or 3000 mg daily, whichever
came ﬁrst.2.3. Data collection
The reason for initiation of niacin therapy, initial pre-niacin data and
last niacin data were recorded. The following parameters were identi-
ﬁed: birthdate, date for ﬁrst and most recent evaluation, comorbidities,
LDL-C, HDL-C, triglyceride, lipoprotein (a) (Lpa), fasting glucose, alanine
transaminase (ALT) and aspartate transaminase (AST). Patients were
speciﬁcally asked about adverse reactions to niacin at each clinic visit
and results were recorded except for initial, occasional, mild ﬂushes at
low doses of niacin. Co-administered lipid medications and reason for
discontinuing niacin, if applicable, were also recorded.2.3.1. Laboratory data
All blood samples were collected in the fasting condition. LDL-C
was computed from the Friedewald equation if triglycerides were
b400 mg/dl. If triglycerides N400 mg/dl, LDL-C was obtained via direct
measurement. If a patient had normal Lpa on the initial sample, no
further Lpa measurements were obtained. If Lpa was abnormal, and
the patient had no recent infection, Lpa was re-measured at full niacin
dosage.2.4. Statistical analysis
To evaluate changes in different lipid panel parameters paired 2 tail
T-tests were used to compare initial and ﬁnal data within each group
(MTG, CTG). Values of p b 0.05 were considered signiﬁcant. Changes
between MTG and CTG and at stratiﬁed lipid levels were tested by
unpaired T-test.3. Results
3.1. Study cohort
Of the 185 eligible patients, 23 patients had missing records leaving
162 patients with available records. Most of those with missing records
were initially evaluated between 1980 and 1995 as some of these
records were purged by the hospital. Of the 162 patients who had
records, 5 never started IRN or never returned for a second visit leaving
157 patients for analysis, all of whom had initial and on treatment data.
However, not all data for Lpa, fasting glucose, ALT, and AST were
available on the last evaluation. In that instance we included analyses
for the prior to ﬁnal visit.
Of the 157 patients with available records, 74 were treated with
MTG and 83 were on the CTG and other lipid lowering medications
such as statin, gembrozil, fenoﬁbrate, or omega 3 fatty acids. 68 of the
83 patients were treated only with the combination of IRN + statins.
These 68 patients will be called the CTG. The mean age for these 157
patients was 55.8 years; mean duration of niacin therapy was 3.05
years. 47% of patients were classiﬁed as secondary prevention and the
remainder as primary prevention. Secondary prevention was deﬁned
as patients having had a documented stroke, myocardial infarction,
coronary bypass surgery, coronary interventional procedures at
catheterization, coronary calcium score N 400, signiﬁcant carotid
atherosclerosis or signiﬁcant peripheral vascular disease.
Data for lipid changes and number of patients for the following
parameters are included in Tables 1-3.3.1.1. LDL-C change
(Data are reported in mg/dl).
Table 1
Effects of IRNa on stratiﬁed lipid levels.
Monotherapy- IRN (n = 74)
Combined therapy group (post-statin + IRN) (n = 68)
# of patients Mean difference P value # of patients Mean difference P value
LDL-Cb 74 −27.16% (143.67–104.64) b.001 68 −22.38% (120.73–93.71) b.001
LDL-C b 100 17 7.42% (85.64–92.00) 0.38 32 6.28% (75.59–80.34) 0.45
LDL-C b 130 29 −6.05% (99.67–93.67) 0.26 37 −10.64% (92.40–82.57) 0.15
LDL-C N=130 45 −35.27% (173.00–111.98) b.001 31 −32.31% (161.19–109.09) b.001
LDL-C N=160 24 −37.67% (196.88–122.67) b.001 12 −33.49% (190.08–126.42) b.05
HDL-Cc 74 +29.84% (53.30–69.20) b.001 68 +34.89% (47.80–64.48) b.001
HDL-C N=40 56 +27.84% (60.16–76.91) b.001 47 +24.36% (60.72–75.51) b.001
HDL-C b 40 18 +40.00% (31.94–44.78) b.001 21 +60.70% (33.57–53.95) b.001
Trid 74 −36.95% (142.16–89.63) b.001 68 −41.78% (164.81–95.95) b.001
Tri b 150 47 −19.13% (85.95–69.51) b.05 49 −27.29% (105.57–76.76) b.001
Tri N=150 27 −47.60% (240.00–125.74) b.001 19 −54.57% (293.94–133.52) b.05
Glucosee 24 +1.90% (98.46–100.33) .75 44 +2.57% (98.91–101.45) .36
ALTf 43 −12.32% (27.56–24.16) .38 62 −0.17% (28.52–28.47) .97
ASTg 43 +15.32% (22.77–26.26) .01 62 +4.01% (27.34–28.44) .33
a IRN = immediate release niacin.
b LDL-C = low density lipoprotein cholesterol.
c HDL-C = high density lipoprotein cholesterol.
d Tri = triglycerides.
e These patients started with normal glucose (b100 mg/dl) and had elevated glucose on niacin therapy.
f ALT = alanine transaminase.
g AST = aspartate transaminase.
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LDL-C decreased27.2% (pb .001) for the 74patients regardless of the
starting LDL-C. For patients with initial LDL-C b 100 (n= 17) and b130
(n = 29), LDL-C changes were not statistically signiﬁcant at +7.4%
(p = .38) and −6.1% (p = .26), respectively. If starting LDL-C was
≥130 mg/dl (n = 45), the mean LDL-C decreased signiﬁcantly
(−35.3%) (p b .001). If initial LDL-C was ≥160 mg/dl (n = 24), the
mean LDL-C decrease was signiﬁcant (−37.7%) (p b .001).Table 2
IRNa effects on the lipid panels of all patients in both groups (MTG + CTG).
# of pt Mean difference P value
LDL-Cb 157 −24.86% (131.62–98.9) b.001
LDL-C b 130 77 −6.11% (93.18–87.48) 0.18
LDL-C N=130 80 −34.73% (168.16–109.75) b.001
LDL-C N=160 38 −37.00% (194.92–122.89) b.001
HDL-Cc 157 +32.37% (50.40–66.72) b.001
HDL-C N 40 105 +27.05% (60.16–76.43) b.001
HDL-C b=40 51(⁎) +53.75% (30.51–46.92) b.001
Trid 157 −39.46% (154.14–92.93) b.001
Tri b 150 102 −20.44% (88.36–71.00) b.001
Tri ≥ 150 55 −50.23% (276.13–132.50) b.001
LPae-initial (elevated)f 48 −49.16% (301.2%-152.13%) b.001
Glucose-whole group 68 +2.33% (98.75–101.06) .50
Glucose-end (elevated)g 17 +17.19% (91.13–106.8) b.001
ALTh-whole group 105 −5.04% (28.12–26.70) .53
ALT-end elevatedi 7 +63.10 (26.71–43.57) b.001
ASTj-whole group 105 +8.15% (25.47–27.54) .14
a IRN = immediate release niacin.
b LDL-C = low density lipoprotein cholesterol.
c HDL-C = high density lipoprotein cholesterol.
d Tri = triglycerides.
e Lp(a) = lipoprotein a.
f Since different testswere used for Lpameasuring,we reported% change. Patientswere
evaluated by the same test each time. Values greater than the upper normal limits were
considered to be elevated. Because statins do not alter Lpa, result for monotherapy and
combined therapy was combined.
g Patients who started with normal glucose (b100 mg/dl) ended with elevated glucose
(N100 mg/dl).
h ALT = alanine transaminase.
i Patientswho startedwithnormal ALT (b35mg/dl) endedwith elevatedALT (N35mg/d).
j AST = aspartate transaminase.
(*): Excluded one patient who started with an HDL-C of 7 and increased to 80 with IRN.3.3. Effect of IRN combined therapy on LDL-C
For all patients already on statin therapy, addition of IRN further re-
duced mean LDL-C 22.4% (n = 68) (p b .001). For patients with statin
LDL-C b100 mg/dl (n = 32) and b130 (n = 37), LDL-C change was
not signiﬁcant at +6.3% (p = .45) and−10.6% (p = .15), respectively.
However, if initial LDL-C on statin therapy was ≥130 (n= 31), addition
of IRN decreased LDL-C further — (32.3%) (p b .001). If LDL-C on statin
therapy was N160 mg/dl (n = 12), addition of IRN caused a further
LDL-C decrease of 33.5% (p b .05).
Comparison ofmean IRNLDL-C induced change inMTG andCTGwas
not signiﬁcantly different. These data show that the further mean
decrease in LDL-C as the result of IRN following statin therapy was es-
sentially identical to the mean decrease in LDL-C from monotherapy.
Data further demonstrate that IRN does not change LDL-C signiﬁcantly
when LDL-C is b130 mg/dl. Additionally when comparing LDL-C values
at b100mg/dl and LDL-C between 100 and 130mg/dl, no signiﬁcant de-
crease occurred. However, the reduction in LDL-C when LDL-C b 130
compared with LDL-C ≥130 achieved statistical signiﬁcance (p b .01)
for both MTG and CTG. (Fig. 1).3.3.1. HDL-C change
(Data are reported in mg/dl).3.4. Effect of mono-therapy IRN on HDL-C
HDL-C increased 29.9% (p b .001) for the 74 patients regardless of
the starting HDL-C. If initial HDL-C was ≥40 (n = 56), HDL-C increasedTable 3
Side effects of IRNa.
n = 157 #of patients Mono-therapy Combined therapy
Flush 36 19 17
Macular edema 3 1 2
Chest pain 1 1 0
Niacin-induced acanthosis 1 0 1
Dry mouth 1 1 0
Signiﬁcant infection 0 0 0
a IRN = immediate release niacin.
Fig. 1. Changes in LDL-C⁎ (MTG vs. CTG). The y-axis displayed the %change in LDL-C after
monotherapy and combined therapy. On the x-axis, the black bar represents the mono-
therapy and the gray bar represents the combined therapy. Three groups of bars represent
how LDL-C changed at different initial stratiﬁed LDL-C levels. Changes in LDL-C b130 is
nonsigniﬁcant, other changes are signiﬁcant. There is no signiﬁcant difference between
themonotherapy and the combined therapy. ⁎LDL-C= low density lipoprotein cholester-
ol. †NS = not signiﬁcant. The lines over bars represent the standard errors.
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HDL-C was 40% (p b .001).
3.5. Effect of IRN combined therapy on HDL-C
When IRNwas added to existing statin therapy, (n=68)meanHDL-
C increased 34.9% (p b .001). If initial HDL-C was ≥40 (n = 47), HDL-C
increased 24.4% (p b .001). If the initial HDL-C on statin therapy was
b40 (n = 21), mean increase in HDL-C was 60.7% (p b .001).
However, there was not a statically signiﬁcant difference of mean
HDL-C change between MTG and CTG which showed that the increase
in HDL-C was constant irrespective of the effect of the statin therapy.
(Fig. 2).
3.5.1. Triglycerides
(Data are reported in mg/dl).
3.6. Effect of mono-therapy IRN on triglycerides
Triglycerides decreased a mean of 37% for 74 patients regardless of
their initial triglycerides level. If the initial triglycerides ≥150 (n =Fig. 2. Changes in HDL-C⁎ and triglycerides (tri) (MTG vs. CTG). The y-axis displayed the
%change in HDL-C and triglycerides after monotherapy and combined therapy. On the
x-axis, the black bar represents the monoRx and the gray bar represents the combined
therapy. Two groups of bars represent HDL-C and triglycerides changes. The lines over
bars represent the standard errors. ⁎HDL-C = high density lipoprotein cholesterol.27), mono-therapy with IRN decreased mean triglycerides by 47.6%
(p b .001).
3.7. Effect of combined therapy on triglycerides
Mean triglycerides decreased 41.8% (p b .001) for 68 patients in the
combined therapy regardless of their initial triglycerides on statin
therapy. If the initial triglycerides ≥150 (n = 19), the mean decrease
in triglycerides was 54.5% (p b .05).
There was not a statically signiﬁcant difference for triglycerides
change between MTG and CTG. (Fig. 2).
3.7.1. Lipoprotein a (Lpa) for patients with initially elevated Lpa
3.7.1.1. Effect of IRN on Lp(a) for both MTG and CTG (n = 48). Lpa
decreased 49.2% for the group with initially elevated Lpa (p b .001). 22
of 48 patients with initially elevated Lpa had values that fell into the
normal range after treatment with IRN.
3.7.1.1.1. Side effects. Table 3 shows adverse effects of INR. Among
157 patients in the study, ﬁve side effects occurred: signiﬁcant ﬂushing
(n = 36), macular edema (n = 3), chest pain (n = 1), niacin induced
acanthosis (n = 1), and dry mouth (n = 1). No patients were found
to have encountered signiﬁcant infections but infection was evaluated
retrospectively. No gastrointestinal bleedingwas reported. Gastrointes-
tinal side effects were not a patient complaint despite their occurrence
in prior studies.
Among these patients, many experienced occasional brief, mild
ﬂushes when taking IRN at 200–250 mg following each meal. 36
patients reported 1 or more signiﬁcant ﬂushes that required additional
aspirin for relief. Three patients ﬂushed repeatedly at 50 mg of IRN and
none of these were able to tolerate high dose IRN. The remainder of
patients continued to high dose INR and was still taking IRN at the
most recent visit.
3.7.1.1.2. Compliance. Three patients stopped niacin therapy because
of uncontrolled ﬂushing and an additional 2 stopped because ofmacular
edema. IRN was reinstituted in one macular edema patient without
recurrence of the problem.
4. Discussion
The most important features of this study were 1) demonstration of
a signiﬁcant decrease of approximately 35% in LDL-C by IRN during
mono-therapy and combined therapy with a statin when LDL-C at
values greater than 130 mg/dl but IRN did not decrease LDL-C
signiﬁcantly when LDL-C was in a lower range (b130 mg/dl). Thus
130 mg/dl appears to be a threshold effect for LDL-C. It is possible that
themajor clinically important effect of niacin is LDL-C reduction. For pa-
tients who are intensively statin treated and have LDL-C in the range
below 130 mg/dl such as occurred in 2 recent studies (AIM-HIGH and
HPS-2-THRIVE), the addition of niacin did not improve outcomes.
These negative resultsmay have occurred because LDL-Cwas not signif-
icantly further lowered by IRN. 2) The general tolerability of IRN the
clinical practice: It has been demonstrated in multiple studies that
reduction of LDL-C reduces cardiovascular risk [16–18]. Although
LDL-C reduction is best accomplished by statin therapy, a substantial
number of patients in clinical practice have muscle pain with daily or
alternate day statin therapy. Some cannot tolerate statins even once
weekly. Muscle pain is ordinarily not a side effect of niacin. Further,
IRN can be used asmono-therapy for patientswith severe statin intoler-
ance or, for those patients who can tolerate statins only 1–4 days/week.
IRN offers an additional option for lowering LDL-C.
In this study, IRN was reasonably tolerated by most patients. The
major side effects, as anticipated, were of cutaneous origin and included
ﬂushing in many patients, itching in a few, and acanthosis in a single
patient. An unexpected ﬁndingwas lack of patient complaints regarding
gastrointestinal side effects. These side effectswere prominent in earlier
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The reason for this lack of gastrointestinal symptoms remains unclear,
but patients may have concentrated more on ﬂushing, or the prepara-
tion we utilized may have had some different characteristics with
respect to the gastrointestinal system than those used previously.
4.1. LDL-C reduction
LDL reduction with statins has been shown to decrease subsequent
cardiovascular endpoints in a variety of studies [16–18]. IRN also
reduced coronary death or nonfatal myocardial infarction signiﬁcantly
in the Coronary Drug Project [6]. However, in the Coronary Drug Project
total serum cholesterol and triglycerides weremeasured, but LDL-C and
HDL-C were not measured or computed. However, it is very likely that
non-HDL was reduced in the Coronary Drug Project and this may have
accounted for decreased events. Subsequent studies have also demon-
strated that LDL-C is signiﬁcantly decreased by IRN [19,20]. Reduction
in LDL-C in the current study was approximately 35%, and this is a
generally similar reduction reported with less intensive statin therapy.
Further, niacin therapy has been reported to have some of the same
pleiotropic effects of statins [21–23]. However, no study is available to
evaluate whether reduction in LDL-C resulting from niacin provides
the same outcome result as a similar reduction in LDL-C by statins.
Nonetheless, if LDL-C reduction is the main target of therapy, niacin
can lower LDL-C.
4.2. IRN increases HDL-C
It remains unclear whether the increase in HDL-C resulting from use
of niacin as demonstrated by this study and others [24,25] is of clinical
importance. Outcome studies showed that raising HDL-C with gemﬁ-
brozil was associated with decreased events, particularly for those
with initially substantially elevated triglycerides [24,25]. However,
those studies also demonstrated a quite signiﬁcant decrease in non-
HDL-C. Further, the HATS trial [11], utilizing simvastatin and a longer
release niacin (and some patients in the HATS study were treated
with immediate release niacin), demonstrated a 90% decrease in the
composite endpoints of cardiovascular events with respect to placebo
group. This 90% event reduction far exceeds event reductions with
statin monotherapy [16–18,26] but the exact reason for the remarkable
event reductions in HATS is unclear. Recently, trials which featured
raising HDL-C with niacin and a statin had different conclusions. In the
AIM HIGH trial, results of extended release niacin with intensive statin
therapy were compared to intensive simvastatin therapy plus placebo
therapy. Although HDL-C increased more in the niacin group, no differ-
ence was found in outcome when the 2 groups were compared. In the
HPS-2-THRIVE study, outcome results of extended release niacin with
laropiprant and simvastatin were compared to outcome results with
simvastatin plus placebo (the placebo included some immediate release
niacin to induce ﬂushing). The results showed no outcome beneﬁt from
the addition of extended release niacin plus laropiprant but did demon-
strate increased side effects including gastrointestinal, dermal issues,
and infections among other side effects. Further, raising HDL-C with
CETP inhibitors added to statin therapy failed to improve cardiovascular
outcomes [15]. Niacin deﬁnitely raises HDL-C, but whether this result is
of clinical importance remains an open question that cannot be evaluat-
ed by the current study. Another study showed that infusing apo A1
Milano decreased plaque volume, but the objective on that study was
not to merely raise HDL-C [27].
4.3. Niacin side effects
The most common side effect of niacin in this study was signiﬁcant
cutaneous ﬂushing (n = 36). Most ﬂushes occurred at approximately
200 mg of IRN. Although few people ﬂushed at lower doses on this
protocol, 3 patients experienced severe ﬂushing at 50 mg of IRN. Twoof the 3 patients reached higher doses, but ﬂushingwas of such severity
that all 3 were advised to discontinue IRN therapy. It is unknown why
some patients experience severe adverse reactions to IRN and most
others have minimal side effects. One common complaint was that
some patients took IRN on an empty stomach or with a minimal meal
and experienced a ﬂush. This was usually alleviated by reiterating that
IRN should be taken after a meal and/or take aspirin to block ﬂushes,
particularly in the beginning of therapy. Almost all patients,with the ex-
ception of the 3 patients who had ﬂushing atminimal IRN doses report-
ed absence or very infrequent or mild ﬂushes as the dose was raised
beyond 200 mg taken with each of the 3 daily meals. For those patients
whoused aspirin, somedevelopedmild bruising but no signiﬁcant hem-
orrhage. Almost all patients were able to discontinue aspirin without
ﬂushing within several months or less.
Some patients increased their niacin dose above 3000 mg/day pre-
sumably to achieve an enhanced effect. This practice was discouraged.
Three patients who increased their daily dose N3000 mg developed
macular edema. This is a known side effect of high-dose niacin and
has been reported to occur in 0.67% of patients taking niacin in doses
of 3000mg/day ormore [28]. The symptom ofmacular edemawas visu-
al blurring. Discontinuing niacin resulted in elimination of macular
edemawithin several days. Two of these patients never restarted niacin.
The third patient who had markedly elevated Lpa and calciﬁc carotid
changes restarted niacin at 2500 mg without further difﬁculty and had
no evidence of macular edema as evaluated periodically by an
ophthalmologist. One patient with metabolic syndrome developed
niacin-induced acanthosis at 1500 mg/day. This is a known but uncom-
mon adverse reaction to niacin. One patient developed dry mouth at
3000 mg but continued taking drug. It is possible that dry mouth was
underreported by patients. Although our study was not designed to
evaluate infections, upon review of the patients, none suffered a signif-
icant infection. However, our study was much smaller than HPS-2-
THRIVE. Additionally, our patients did not take laropiprant. Laropiprant,
a drug initially studied for relieving allergic symptoms, has not been
approved for use in the United States by the FDA. It has been reported
to cause adverse reactions in Europe with or without niacin. HPS-2-
THRIVE was a study of niacin + laropiprant and it is unclear whether
non-ﬂushing side effects in HPS-2-THRIVE resulted from niacin or
laropiprant or a combination of the two drugs. Further, no patient in
the currently study had a cardiovascular event while taking IRN, but
our study may have been too small to have observed an event.
4.4. Effects of IRN on Lpa
In the current study only individuals with elevated Lpa had an anal-
ysis for percent change. Percent change for those with initially elevated
Lpawas a 45% decrease. A generally similar reductionwas noted in both
the mono-therapy group and the combined therapy group which was
expected since statins do not alter Lpa levels. Our results are somewhat
similar to those in Carlson [29].(mean Lpa decrease = −38%) even
though they use higher doses of niacin (4 g), but they did not exclude
individuals with initially normal Lpa. A further ﬁnding in the study of
Carlson et al. was the demonstration that the reduction in Lpa was
essentially linear with respect to the decrease in LDL-C. Although niacin
has been shown to generally decrease or reverse the deposition of
atherosclerotic plaque [12], no outcome study of Lpa reduction has
been performed.
The use of IRN may require more physician–patient discussion time
than for extended release niacin. Best results appeared to occur with
detailed explanation of the protocol which uses increasing doses of
IRN and the use of the prostaglandin inhibitor, aspirin. The protocol
used in this study was adopted to allow very gradual increase in IRN
dosing. The slow increase allows patients to gain conﬁdence at relatively
low doses, usually with no ﬂushes. Flushes, when they occur, usually
begin within the ﬁrst 20 min following ingestion of IRN and are usually
quite brief lasting 5–10 min. Use of 81 mg of aspirin usually eliminates
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chewable variety in order to get quicker absorption. Use of coated
aspirin is usually not as effective because the ﬂush occurs before the
aspirin is absorbed. Patients who did have a signiﬁcant ﬂush usually
obtained relief within 5 to 10 min by chewing three 81 mg aspirin and
drinking a large glass of water which improved aspirin dissolution and
absorption.
4.5. Study limitations
Our retrospective study has deﬁnite limitations. The population size
was relatively small with 157 patients. However, with limited indica-
tions it is difﬁcult to have a large population in a clinical setting. Some
early medical records had been purged and even though some of
these patients remain in our practice, their initial values were no longer
available and thus these patients were not included in the study. Our
data were not collected at exactly the same time points for all patients
and thus it is not possible to do any time relationships. The estimates
of ﬂushing may be underreported since we did not keep a detailed
record of individuals who experienced early treatment minor or brief
ﬂushes. The authors were surprised by the lack of complaints regarding
gastrointestinal symptoms as reported in other studies. The signiﬁcance
of this lack of gastrointestinal side effects remains unclear. Finally, this
study is not an outcome study.
5. Conclusion
The results of this study offer insight into a possible reason why
some outcome studies did not show signiﬁcant beneﬁt with niacin
combined with a statin. Niacin does not substantially decrease LDL-C
when LDL-C is b130 but signiﬁcantly lowers LDL-C N130 when used
as monotherapy or in combination with a statin. In HPS-2-THRIVE
niacin was added after LDL-C was b70 mg/dl. Niacin increases HDL-C,
but the signiﬁcance of increasing HDL-C with medications will await
outcome studies in which LDL-C and triglycerides are unchanged and
HDL levels are altered.
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